60.48
Precedente Chiudi:
$61.74
Aprire:
$62.2
Volume 24 ore:
525.81K
Relative Volume:
0.87
Capitalizzazione di mercato:
$3.80B
Reddito:
$112.53M
Utile/perdita netta:
$-258.91M
Rapporto P/E:
-13.97
EPS:
-4.33
Flusso di cassa netto:
$-124.42M
1 W Prestazione:
+0.57%
1M Prestazione:
+16.22%
6M Prestazione:
+20.50%
1 anno Prestazione:
+59.12%
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Nome
Rhythm Pharmaceuticals Inc
Settore
Industria
Telefono
857-264-4280
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Confronta RYTM con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RYTM
Rhythm Pharmaceuticals Inc
|
60.48 | 3.80B | 112.53M | -258.91M | -124.42M | -4.33 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-07 | Aggiornamento | BofA Securities | Neutral → Buy |
2025-03-05 | Ripresa | Stifel | Buy |
2025-01-02 | Iniziato | Jefferies | Buy |
2024-12-20 | Iniziato | Oppenheimer | Outperform |
2024-10-21 | Iniziato | Guggenheim | Buy |
2024-09-18 | Iniziato | H.C. Wainwright | Buy |
2024-09-17 | Iniziato | JMP Securities | Mkt Outperform |
2024-05-08 | Downgrade | BofA Securities | Buy → Neutral |
2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2023-08-01 | Aggiornamento | BofA Securities | Neutral → Buy |
2023-01-18 | Ripresa | Canaccord Genuity | Buy |
2022-08-08 | Aggiornamento | Goldman | Neutral → Buy |
2022-08-05 | Aggiornamento | BofA Securities | Underperform → Neutral |
2022-06-17 | Reiterato | Needham | Buy |
2022-03-02 | Ripresa | Stifel | Buy |
2022-02-17 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
2021-12-08 | Iniziato | Wells Fargo | Overweight |
2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-09-14 | Ripresa | Goldman | Neutral |
2021-08-04 | Downgrade | BofA Securities | Neutral → Underperform |
2021-08-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
2020-11-30 | Downgrade | BofA Securities | Buy → Neutral |
2020-01-08 | Iniziato | Goldman | Sell |
2019-07-12 | Aggiornamento | Stifel | Hold → Buy |
2019-07-08 | Iniziato | Canaccord Genuity | Buy |
2019-03-13 | Iniziato | Ladenburg Thalmann | Buy |
2018-09-07 | Ripresa | Morgan Stanley | Overweight |
2018-06-25 | Reiterato | Needham | Buy |
2018-06-15 | Reiterato | Needham | Buy |
2017-10-30 | Iniziato | BofA/Merrill | Buy |
2017-10-30 | Iniziato | Needham | Buy |
Mostra tutto
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results - markets.businessinsider.com
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - MSN
Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded at Bank of America - MarketBeat
Canaccord maintains Buy on Rhythm Pharma following Ph3 data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Target Price Raised by BofA Amid P - GuruFocus
Rhythm Pharmaceuticals EVP Yann Mazabraud sells $1.08 million in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound - GuruFocus
Rhythm Pharmaceuticals Stock (RYTM) Erases YTD Losses This Week - AskTraders.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target By Investing.com - Investing.com Canada
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - MSN
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade - MSN
Rhythm’s setmelanotide cuts BMI by 20% - The Pharma Letter
Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug - TradingView
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating - marketscreener.com
Canaccord raises Rhythm Pharma stock target to $92, maintains buy - Investing.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target - Investing.com
Rhythm Pharmaceuticals shares rise on raised target to $80 By Investing.com - Investing.com UK
Canaccord raises Rhythm Pharma stock target to $92, maintains buy By Investing.com - Investing.com Canada
Positive Phase 3 Results and Market Potential Boost Rhythm Pharmaceuticals’ Price Target - TipRanks
BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 - Investing.com Australia
Rhythm Pharmaceuticals (RYTM) Surges as Obesity Drug Achieves Ke - GuruFocus
Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News
Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success - insights.citeline.com
Rhythm Pharmaceuticals’ Bold Moves: What’s Next? - timothysykes.com
Rhythm Pharmaceuticals price target raised to $77 from $72 at Morgan Stanley - TipRanks
Rhythm posts late-stage trial win for lead asset against rare form of obesity - MSN
Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish - MSN
BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 By Investing.com - Investing.com Canada
Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha
Rhythm Pharmaceuticals (RYTM) Achieves Success in Phase 3 Obesit - GuruFocus
Rhythm Pharmaceuticals Plans Regulatory Filings After Positive I - GuruFocus
Why Rhythm Pharmaceuticals Stock is Climbing High - TipRanks
Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder - Yahoo
Rhythm Pharmaceuticals’ Unexpected Surge: A Stock to Watch? - timothysykes.com
Rhythm Pharma's drug for rare obesity meets late-stage trial goal - MSN
Rhythm Pharmaceuticals (RYTM) Reports Promising Phase 3 Trial Re - GuruFocus
Rhythm Pharmaceuticals (RYTM) Achieves Phase 3 Trial Success wit - GuruFocus
Rhythm Pharmaceuticals stock rises on trial success By Investing.com - Investing.com India
Rhythm Pharmaceuticals stock rises on trial success - Investing.com Australia
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in trial - MSN
Rhythm Pharmaceuticals' Obesity Treatment Meets Main Goal in Phase 3 Study, Shares Rise - MarketScreener
Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity - MarketScreener
Rhythm Pharmaceuticals Announces Positive Phase 3 Trial Results - TipRanks
Rhythm Pharmaceuticals says Phase 3 TRANSCEND trial meets primary endpoint - TipRanks
Rhythm Pharma Reports Positive Topline Results From Phase 3 TRANSCEND Trial With Setmelanotide - Nasdaq
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial - MarketScreener
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - GlobeNewswire
Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):